Purpose: We evaluated the interest of systematic screening of serum fungal markers in patients hospitalized in a medical ward.
Methods: We retrospectively analyzed all patients hospitalized in our infectious disease department from October 1st to October 31st, 2020 for COVID-19 without prior ICU admission, and for whom systematic screening of serum fungal markers was performed.
Results: Thirty patients were included. The majority of patients received corticosteroids (96.7%). The galactomannan antigen assay was positive for 1/30 patients at D0, and 0/24, 0/16, 0/13 and 0/2 at D4, D7, D10 and D14 respectively. 1,3-ß-D-glucan was positive for 0/30, 1/24, 1/12, 0/12, 0/2 at D0, D4, D7, D10 and D14 respectively. No Aspergillus fumigatus PCR was positive. No cases of aspergillosis were retained.
Conclusion: Our study does not support the interest of systematic screening of fungal markers in immunocompetent patients with COVID-19 in a conventional unit.
Keywords: Aspergillosis; COVID-19; COVID-19-associated pulmonary aspergillosis; Fungal screening.
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.